Plasma syndecan-1 decline was less pronounced in comatose OHCA patients treated with tocilizumab, without affecting sTM or PECAM-1. This contrasts previous IMICA findings of reduced systemic inflammation, vasopressor use, and myocardial injury, suggesting a complex relationship between inflammation and endothelial injury.Finally, PECAM-1 levels already at hospital admission had a moderate predictive value for mortality.
Alaoui-Ismaili et al. (Sun,) studied this question.